Bicycle Therapeutics plc (NASDAQ:BCYC) announced that it presented data showing the enhanced anti-tumor activity of ...

Craig A Clifford, DVM, MS, DACVIM (Oncology) talks about the most common bladder tumor in dogs, misdiagnosis, and the Cadet ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Tuesday said that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation to Trodelvy for the treatment of adults with ...

A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...

Updated results from the CheckMate 274 trial support the use of adjuvant nivolumab as standard care for high-risk muscle-invasive urothelial carcinoma, according to researchers.

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...

Bicycle Therapeutics plc, a company specializing in developing therapeutic solutions based on its proprietary bicyclic peptide technology, revealed significant data updates across its zelenectide ...

Brenetafusp is a fusion protein commercialized by Immunocore, with a leading Phase III program in Melanoma. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData ...

Recent progress in understanding epigenetic modification and gene silencing has led to new opportunities for the understanding, detection, treatment and prevention of cancer. Moreover, epigenetic ...

TPST-1120 is a small molecule commercialized by Tempest Therapeutics, with a leading Phase II program in Metastatic Hepatocellular Carcinoma (HCC).

EQS-News: CHEPLAPHARM AG / Key word (s): Mergers & Acquisitions CHEPLAPHARM acquires Gemzar from Lilly 16.12.2024 / 08:48 CET/CEST The issuer is solely responsible for the content of this ...

Mergers & AcquisitionsCHEPLAPHARM acquires Gemzar from Lilly 16.12.2024 / 08:48 CET/CESTThe issuer is solely responsible for the content of this announcement.CHEPLAPHARM ACQUIRES GEMZAR® FROM ...